HSV-1 Persistence: Latency, Reactivation Triggers & Immune Evasion

How Herpes Simplex Virus Type 1 Establishes Lifelong Infection

After primary infection (often asymptomatic or causing gingivostomatitis), HSV-1 travels via sensory nerve axons to the trigeminal ganglia, where it establishes latency—a dormant state with minimal viral gene expression. The viral genome persists as an episome in neuronal nuclei, invisible to immune surveillance.

Mechanisms of Persistence

1. Immune Evasion During Lytic Infection

• ICP47 blocks TAP transporter → inhibits MHC class I presentation to CD8⁺ T cells
• gC, gE/gI bind complement components and IgG Fc, neutralizing antibody and complement attack
• US3 kinase inhibits apoptosis, prolonging infected cell survival

2. Latency-Associated Transcript (LAT)

• Only abundant viral RNA during latency; non-coding
• Anti-apoptotic: protects neuron from cell death
• Epigenetically regulates viral genome chromatin (heterochromatin vs. euchromatin) to maintain silence
• May modulate host miRNA pathways

3. Neuronal Sanctuary

• Neurons are non-dividing, low MHC class I expressors—poor targets for cytotoxic T lymphocytes
• Blood-nerve barrier limits immune cell access

4. Genetic Variability

HSV-1 exhibits genomic diversity; mutations in epitopes can reduce T-cell recognition, though less pronounced than in RNA viruses.

Reactivation: From Latency to Lesion

Triggers disrupt neuronal homeostasis, prompting viral genome reactivation:

• Ultraviolet (UV) radiation (sunlight) – most common trigger for herpes labialis
• Psychological/physical stress (cortisol, catecholamines)
• Fever, systemic illness
• Hormonal fluctuations (menstruation)
• Local trauma (dental work, abrasion)
• Immunosuppression (chemotherapy, steroids, HIV)

Reactivated virus travels anterogradely down axons to mucosal/skin epithelium → productive replication → cold sore (herpes labialis) or, less commonly, herpetic keratitis, encephalitis, or genital lesions (via oral-genital contact).

Clinical Implications

• No cure exists; antivirals (acyclovir, valacyclovir) suppress replication but don't eradicate latent reservoir
• Daily suppressive therapy reduces recurrence frequency and asymptomatic shedding
• Vaccine development focuses on preventing primary infection or boosting T-cell control of latency

Key Takeaway

HSV-1 persistence relies on neuronal latency, active immune evasion, and epigenetic silencing. Reactivation is stochastic but triggered by identifiable stressors. Understanding these mechanisms informs management and future therapeutic strategies.